Lethal Legionella Pneumonia With Bacteremia Due to Serotype 3 Co-infected With Staphylococcus aureus and Haemophilus influenzae
Abstract
A 66-year-old man with no relevant medical history developed pneumonia. Urine antigen tests for pneumococcus and Legionella serotype 1 (the most common serotype) were negative, but sputum culture was positive for methicillin-susceptible Staphylococcus aureus (MSSA) and β-lactamase-negative Haemophilus influenzae (BLNAR). The patient was treated with meropenem and azithromycin, but an aerobic blood culture became positive on day 4, and mass spectrometry analysis indicated the presence of Legionella species. Subculture on buNrNL charcoal yeast extract (BCYE)-α agar identified Legionella pneumophila serotype 3. The patient was diagnosed with pneumonia caused by MSSA and BLNAR, as well as pneumonia/bacteremia due to Legionella pneumophila serotype 3. Despite changing the antibiotics to meropenem plus lascufloxacin and adding hydrocortisone and venovenous extracorporeal membrane oxygenation (V-V ECMO), the patient died. In patients with severe pneumonia, co-infection with Legionella species, including rare serotypes, should be considered, and universal rapid antigen tests are necessary to ensure rapid diagnosis and appropriate treatment.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.